Rima Alkasem
Neurology · Philadelphia, PANPI 1700041662
Payments from drug & device makers
Across 20 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$98
- Lilly USA, LLC$73
- Johnson & Johnson$54
- AstraZeneca$48
- Lundbeck LLC$23
- Sumitomo Pharma America, Inc.$23
- plus $93 from 5 others
What the payments were for
- Food & beverage$413100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $98 |
| Lilly USA, LLC | 4 | $73 |
| Johnson & Johnson | 2 | $54 |
| AstraZeneca | 2 | $48 |
| Lundbeck LLC | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| SK Life Science, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
How this compares
$413 in reported general payments places this provider in the 35th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $85,190 |
| Emgality PenGalcanezumab-Gnlm | 31 | $30,955 |
| Lacosamide | 49 | $7,842 |
| Carbamazepine ErCarbamazepine | 25 | $4,228 |
| Levetiracetam | 94 | $3,766 |
| Memantine Hcl ErMemantine Hcl | 21 | $1,718 |
| Clobazam | 12 | $1,384 |
| Topiramate | 64 | $1,115 |
| Memantine Hcl | 22 | $894 |
| Gabapentin | 57 | $887 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 13 | $720 |
| Donepezil Hcl | 54 | $651 |
| Divalproex Sodium | 29 | $648 |
| Alprazolam | 26 | $317 |
| Escitalopram Oxalate | 13 | $276 |
Paid to pharmacies, not to this prescriber.
Other neurology in Philadelphia
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
- Andres Deik Acosta MadiedoPhiladelphia$1.8M
- Michael SperlingPhiladelphia$1.7M
- Sanjeev VaishnaviPhiladelphia$1.6M
- Andrew SiderowfPhiladelphia$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.